Send a text

🧠 Clinical Context

Hydrochlorothiazide (HCTZ) vs. Chlorthalidone—a classic cardio debate! ALHAT once hinted at chlorthalidone’s superiority, but did a modern head-to-head trial confirm that? Let's break it down.

🧪 Study Snapshot: The HEADS-UP Trial

• Design: Randomized, head-to-head trial
• Population: ~14,000 patients, age ≥65, already on HCTZ 25–50 mg + 1–2 antihypertensives
• Prior CV disease: 15% had MI, stroke, or HF
• Groups:
  • Continue HCTZ
  • Switch to Chlorthalidone 12.5–25 mg daily
• Follow-up: Median 2.4 years

📈 Outcomes

• Primary endpoint: Composite of MI, stroke, HF, urgent revascularization, or non-cancer death
  → Occurred in 10% of both groups
• BP Control: No significant difference
• Hypokalemia:
  • Chlorthalidone: 4.4%
  • HCTZ: 6.0%

💡 What About CKD?

• 23% had GFR <60 at baseline, but…
• No strong data on severely reduced renal function for HCTZ
• In a 12-week placebo-controlled study, chlorthalidone lowered BP in GFR 15–30, but HCTZ didn’t have similar data
• Still, in randomized trials: no difference in mortality or cardiovascular outcomes

⚠️ Surprises & Caveats

• Despite historical bias toward chlorthalidone, outcomes and BP control were equivalent
• Hypokalemia was actually slightly lower with chlorthalidone
• More robust data is still needed for advanced CKD patients

🧩 Clinical Takeaway

Despite all the hype, chlorthalidone isn’t clearly superior. In practice, both meds perform similarly for hypertension control and cardiovascular outcomes in older adults. But if your patient has significantly impaired renal function, chlorthalidone may edge ahead—at least for now.

💬 Bottom line? Choose the thiazide based on patient profile, tolerance, and renal function—not legacy dogma.